194 related articles for article (PubMed ID: 34473271)
1. Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints.
Abbott IJ; Mouton JW; Peleg AY; Meletiadis J
J Antimicrob Chemother; 2021 Nov; 76(12):3201-3211. PubMed ID: 34473271
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy.
Abbott IJ; van Gorp E; Wijma RA; Meletiadis J; Mouton JW; Peleg AY
J Microbiol Methods; 2020 Apr; 171():105861. PubMed ID: 32035114
[TBL] [Abstract][Full Text] [Related]
3. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.
Abbott IJ; Meletiadis J; Belghanch I; Wijma RA; Kanioura L; Roberts JA; Peleg AY; Mouton JW
J Antimicrob Chemother; 2018 Mar; 73(3):709-719. PubMed ID: 29253153
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.
Abbott IJ; van Gorp E; Wijma RA; Dekker J; Croughs PD; Meletiadis J; Mouton JW; Peleg AY
J Antimicrob Chemother; 2020 Jul; 75(7):1879-1888. PubMed ID: 32361749
[TBL] [Abstract][Full Text] [Related]
5. Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic
Abbott IJ; van Gorp E; van der Meijden A; Wijma RA; Meletiadis J; Roberts JA; Mouton JW; Peleg AY
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253214
[TBL] [Abstract][Full Text] [Related]
6. Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections.
Abbott IJ; Dekker J; van Gorp E; Wijma RA; Raaphorst MN; Klaassen CHW; Meletiadis J; Mouton JW; Peleg AY
J Antimicrob Chemother; 2020 Apr; 75(4):988-996. PubMed ID: 31873748
[TBL] [Abstract][Full Text] [Related]
7. Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against
Abbott IJ; van Gorp E; Wijma RA; Meletiadis J; Roberts JA; Mouton JW; Peleg AY
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907184
[TBL] [Abstract][Full Text] [Related]
8. Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.
Abbott IJ; van Gorp E; Wyres KL; Wallis SC; Roberts JA; Meletiadis J; Peleg AY
J Antimicrob Chemother; 2022 Apr; 77(5):1324-1333. PubMed ID: 35211736
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study.
Karlowsky JA; Baxter MR; Walkty AJ; Lagacé-Wiens PRS; Bay D; Adam HJ; Zhanel GG
J Antimicrob Chemother; 2022 Oct; 77(11):3035-3038. PubMed ID: 35971759
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Evaluation of the Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales, Enterococcus faecalis, and Staphylococcus Species.
Goer A; Blanchard LS; Van Belkum A; Loftus KJ; Armstrong TP; Gatermann SG; Shortridge D; Olson BJ; Meece JK; Fritsche TR; Pompilio M; Halimi D; Franceschi C
J Clin Microbiol; 2022 Jul; 60(7):e0002122. PubMed ID: 35736011
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections.
Wangchinda W; Pogue JM; Thamlikitkul V; Leelawattanachai P; Koomanachai P; Pai MP
J Antimicrob Chemother; 2024 Jun; 79(6):1372-1379. PubMed ID: 38597137
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.
Lu CL; Liu CY; Huang YT; Liao CH; Teng LJ; Turnidge JD; Hsueh PR
Antimicrob Agents Chemother; 2011 Sep; 55(9):4295-301. PubMed ID: 21670185
[TBL] [Abstract][Full Text] [Related]
14.
Gill CM; Nicolau DP
Antimicrob Agents Chemother; 2023 May; 67(5):e0173822. PubMed ID: 37022170
[TBL] [Abstract][Full Text] [Related]
15. Establishment of epidemiological cut-off values for cefoselis, a new fourth-generation cephalosporin, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis and Pseudomonas aeruginosa.
Li X; Jia P; Zhu Y; Xu Y; Yu Y; Lv Y; Wang M; Sun Z; Lin J; Li Y; Zheng B; Hu F; Guo Y; Chen Z; Li H; Zhang G; Zhang J; Kang W; Duan S; Wang T; Jing R; Yang Q
J Antimicrob Chemother; 2021 Sep; 76(10):2593-2599. PubMed ID: 34215878
[TBL] [Abstract][Full Text] [Related]
16. Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test.
Croughs PD; Konijnendijk-de Regt M; Yusuf E
Microbiol Spectr; 2022 Apr; 10(2):e0250421. PubMed ID: 35352940
[TBL] [Abstract][Full Text] [Related]
17. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
Neuner EA; Sekeres J; Hall GS; van Duin D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5744-8. PubMed ID: 22926565
[TBL] [Abstract][Full Text] [Related]
18. Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.
Hirsch EB; Raux BR; Zucchi PC; Kim Y; McCoy C; Kirby JE; Wright SB; Eliopoulos GM
Int J Antimicrob Agents; 2015 Dec; 46(6):642-7. PubMed ID: 26498988
[TBL] [Abstract][Full Text] [Related]
19.
Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
[TBL] [Abstract][Full Text] [Related]
20. Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and
Zheng D; Bergen PJ; Landersdorfer CB; Hirsch EB
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0144621. PubMed ID: 34807759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
